Inhibrx Biosciences (INBX) Stock Price, News & Analysis

Company Overview

Inhibrx, Inc., headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration. INBRX-109 is being evaluated in early-stage clinical studies for indications such as chronic wounds and tissue damage. In addition to its ROR2 program, Inhibrx is advancing a pipeline of preclinical assets targeting pathways including Tie2 and neuropilin-2 (NRP2), each selected for their potential to modulate angiogenesis, immune responses or fibrotic processes.

Founded in 2006, Inhibrx completed its initial public offering in 2016 and trades on the Nasdaq under the ticker INBX. The company collaborates with academic research centers and strategic industry partners to accelerate the translation of its engineered proteins from discovery through clinical development. Inhibrx’s leadership team brings together expertise in molecular biology, protein engineering, translational science and regulatory affairs to drive the advancement of its therapeutic candidates toward potential regulatory approval.

Key Stats

• Today's Range: $90.88 to $96.09
• 50-Day Range: $58.39 to $141.84
• 52-Week Range: $12.80 to $155.29
• Volume: 328,004 shs
• Average Volume: 488,111 shs
• Market Capitalization: $1.40 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $150.00
• Consensus Rating: Hold

Inhibrx Biosciences Stock Analysis - MarketRank™

Inhibrx Biosciences scored higher than 47% of companies evaluated by MarketBeat, and ranked 605th out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Hold

Consensus Rating

Inhibrx Biosciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 strong buy rating, 1 buy rating, 3 hold ratings, and 1 sell rating.

Upside Potential

Inhibrx Biosciences has a consensus price target of $150.00, representing about 57.5% upside from its current price of $95.22.

Amount of Analyst Coverage

Inhibrx Biosciences has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Inhibrx Biosciences are expected to grow in the coming year, from ($10.15) to ($7.67) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Inhibrx Biosciences is -11.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Inhibrx Biosciences is -11.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Inhibrx Biosciences has a P/B Ratio of 173.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

24.11% of the float of Inhibrx Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Inhibrx Biosciences has a short interest ratio ("days to cover") of 4.48.

Change versus previous month

Short interest in Inhibrx Biosciences has recently increased by 7.28%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Inhibrx Biosciences does not currently pay a dividend.

Dividend Growth

Inhibrx Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.93

News Sentiment

Inhibrx Biosciences has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Inhibrx Biosciences this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for INBX on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Inhibrx Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

18.26% of the stock of Inhibrx Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

82.46% of the stock of Inhibrx Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 6/03/2026
• Next Earnings (Estimated): 8/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:INBX
• CIK: 2007919
• Web: www.inhibrx.com
• Phone: 858-795-4220
• Fax: N/A
• Employees: 166
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Inhibrx Biosciences: $150.00
• High Price Target: $150.00
• Low Price Target: $150.00
• Potential Upside/Downside: +57.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($8.39)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$140.05 million
• Net Margins: N/A
• Pretax Margin: -10,014.08%
• Return on Equity: -563.90%
• Return on Assets: -72.32%

Debt

• Debt-to-Equity Ratio: 12.58
• Current Ratio: 6.46
• Quick Ratio: 6.46

Sales & Book Value

• Annual Sales: $1.30 million
• Price / Sales: 1,074.52
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.55 per share
• Price / Book: 173.13

Miscellaneous

• Outstanding Shares: 14,670,000
• Free Float: 11,992,000
• Market Cap: $1.40 billion
• Optionable: Optionable
• Beta: 3.31